Agenus' bot/bal neoadjuvant pan-cancer data from the neoasis study presented in an oral session at aacr

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today announced that data from the investigator sponsored neoasis study were presented in an oral session at the american association for cancer research (aacr) annual meeting in chicago, illinois. this represents the third clinical study evaluating botensilimab and balstilimab (bot/bal) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pmmr/mss) and mismatch repair–defici.
AGEN Ratings Summary
AGEN Quant Ranking